CiVi Biopharma A/S — Credit Rating and Financial Key Figures

CVR number: 38027794
Sundkrogsgade 21, 2100 København Ø

Income statement (kDKK)

2019
2020
2021
2022
2023
Fiscal period length1212121212
Net sales
Gross profit7 236.694 484.624 035.573 530.113 502.14
Employee benefit expenses-6 393.99-3 969.54-3 582.80-3 099.95-3 100.37
EBIT842.70515.08452.77430.16401.77
Other financial income1.01
Other financial expenses-9.89-11.95-10.93-10.78-3.19
Reduction non-current investment assets-2 196.94
Pre-tax profit833.81503.14441.84419.38-1 798.36
Income taxes- 185.09- 111.17-97.83-93.06-88.97
Net earnings648.73391.97344.00326.32-1 887.33

Assets (kDKK)

2019
2020
2021
2022
2023
Intangible assets total
Tangible assets total
Investments total18.33
Long term receivables total
Inventories total
Current amounts owed by group member comp.3 091.131 448.411 725.293 488.241 750.00
Prepayments and accrued income40.0880.5582.88100.5179.56
Current other receivables73.22103.97154.50109.88109.59
Current deferred tax assets9.8387.1716.52
Short term receivables total3 204.431 642.772 049.833 698.631 955.67
Cash and bank deposits1 375.822 471.542 282.32248.91329.45
Cash and cash equivalents1 375.822 471.542 282.32248.91329.45
Balance sheet total (assets)4 598.584 114.314 332.153 947.542 285.13

Equity and liabilities (kDKK)

2019
2020
2021
2022
2023
Share capital500.00500.00500.00500.00500.00
Retained earnings1 164.331 813.062 205.032 549.032 875.35
Profit of the financial year648.73391.97344.00326.32-1 887.33
Shareholders equity total2 313.062 705.033 049.033 375.351 488.02
Non-current liabilities total
Current trade creditors112.323.62133.71302.52483.22
Short-term deferred tax liabilities42.0911.0640.21
Other non-interest bearing current liabilities2 131.111 405.661 149.40258.61273.68
Current liabilities total2 285.521 409.281 283.11572.19797.11
Balance sheet total (liabilities)4 598.584 114.314 332.153 947.542 285.13
Try the full version of our system for free
Bankruptcy risk visualization example

... and more!

No registration needed.